What does Elevidys mean for future drug approvals?
Elevidys is now a reference case for accelerated-approval reform alongside Exondys 51 and Aduhelm — and the FDA's 2025 interventions, plus a 9-3 advisory vote against another DMD therapy in August 2026, suggest a more sceptical posture is spreading across the field.
Elevidys has become a reference case in the debate over the FDA's accelerated approval pathway and the role of senior officials in overriding scientific staff. It sits alongside Sarepta's own Exondys 51 and Biogen's Aduhelm as examples critics cite when arguing that surrogate endpoints have been accepted too readily. At the same time, the FDA's actions in 2025, including the platform designation revocation and the request to halt shipments, suggest a more interventionist posture under current leadership. In August 2026 an FDA advisory committee voted 9-3 against another DMD therapy, deramiocel, indicating scepticism is spreading across the field. For patients, the practical question is whether benefits in ambulatory boys will be borne out over time, and whether liver risks can be managed.